Roche has acquired exclusive global rights to develop, manufacture, and commercialise SIM0660, a trispecific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases.  Under the terms of the agreement, developer Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including $75 million in upfront. Simcere Zaiming is also […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!